Bisacodyl: Difference between revisions

(Created page with "==Administration== *Type: laxative *Dosage Forms: *Routes of Administration: Oral, suppository *Common Trade Names: Ducolax ==Adult Dosing== *5-30 mg PO daily *10mg supposito...")
 
(Marked this version for translation)
 
(8 intermediate revisions by 6 users not shown)
Line 1: Line 1:
==Administration==
<languages/>
*Type: laxative
<translate>
*Dosage Forms:
*Routes of Administration: Oral, suppository
*Common Trade Names: Ducolax


==Adult Dosing==
==Administration== <!--T:1-->
*5-30 mg PO daily
 
<!--T:2-->
*Type: [[Special:MyLanguage/laxative|laxative]]
*Dosage Forms: tablet, enema, suppository
*Dosage Strengths: tablet: 5mg; enema: 10mg/30mL; suppository: 10mg
*Routes of Administration: PO, PR
*Common Trade Names: Dulcolax, Correctol, BisacEvac, Bisacolax, Codulax, Alophen, Feen A Mint, Fleet Stimulant Laxative, Laxit, Modane
 
 
==Adult Dosing== <!--T:3-->
 
<!--T:4-->
*5-30mg PO daily
*10mg suppository daily
*10mg suppository daily


==Pediatric Dosing==
 
*6-11 yrs: 5 mg or rectally daily
==Pediatric Dosing== <!--T:5-->
==Special Populations==
 
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: A
<!--T:6-->
*[[Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out
*6-11 yrs: 5mg or rectally daily
===Renal Dosing===
 
==Special Populations== <!--T:7-->
 
<!--T:8-->
*[[Special:MyLanguage/Drug Ratings in Pregnancy|Pregnancy Rating]]: A
*[[Special:MyLanguage/Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out
 
===Renal Dosing=== <!--T:9-->
 
<!--T:10-->
*Adult:
*Adult:
*Pediatric:
*Pediatric:
===Hepatic Dosing===
 
===Hepatic Dosing=== <!--T:11-->
 
<!--T:12-->
*Adult:
*Adult:
*Pediatric:
*Pediatric:


==Contraindications==
 
==Contraindications== <!--T:13-->
 
<!--T:14-->
*Allergy to class/drug
*Allergy to class/drug
*Appendicitis
*Appendicitis
*Bowel obstruction
*Bowel obstruction
*Gastroenteritis
*Gastroenteritis
==Adverse Reactions==
 
===Serious===
==Adverse Reactions== <!--T:15-->
 
 
===Serious=== <!--T:16-->
 
<!--T:17-->
*Colonic atony
*Colonic atony
===Common===
 
===Common=== <!--T:18-->
 
<!--T:19-->
*Abdominal discomfort/colic, diarrhea, proctitis (with suppository use)
*Abdominal discomfort/colic, diarrhea, proctitis (with suppository use)
==Pharmacology==
*Half-life:
*Metabolism:
*Excretion:


==Mechanism of Action==
==Pharmacology== <!--T:20-->
 
<!--T:21-->
*Half-life: 8 hr
*Metabolism: Metabolized to BHPM in the colon
*Excretion: Urine and bile
 
 
==Mechanism of Action== <!--T:22-->
 
<!--T:23-->
*Stimulates peristalsis via parasympathetic reflexes
*Stimulates peristalsis via parasympathetic reflexes
==Comments==


==See Also==
==Comments== <!--T:24-->
*[[Constipation]]
 
==References==
 
==See Also== <!--T:25-->
 
<!--T:26-->
*[[Special:MyLanguage/Constipation|Constipation]]
 
==References== <!--T:27-->
 
<!--T:28-->
*Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
*Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
*Christie J, Rose S. Constipation, diarrhea, hemorrhoids, and fecal incontinence. In: Pregnancy in gastrointestinal disorders. Bethesda (MD): ACG Monograph American College of Physicians; 2007. p. 4–9. Available at https://www.acg.gi.org
*Ducodyl (bisacodyl) [prescribing information]. Troy, MI: Prime Marketing; received January 2019.
*Friedrich C, Richter E, Trommeshauser D, et al, "Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate Into Human Breast Milk: An Open-Label, Parallel-Group, Multiple-Dose Study in Healthy Lactating Women," Drug Metab Pharmacokinet, 2011, 26(5):458-64. [PubMed 21697613]
*"Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics.1997;99(2):268-278. [PubMed 9024461]
*Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. [PubMed 24345831]
 
<!--T:29-->
<references/>
<references/>
[[Category:Pharmacology]]
[[Category:Pharmacology]] [[Category:GI]]
</translate>

Latest revision as of 21:24, 6 January 2026

Other languages:

Administration

  • Type: laxative
  • Dosage Forms: tablet, enema, suppository
  • Dosage Strengths: tablet: 5mg; enema: 10mg/30mL; suppository: 10mg
  • Routes of Administration: PO, PR
  • Common Trade Names: Dulcolax, Correctol, BisacEvac, Bisacolax, Codulax, Alophen, Feen A Mint, Fleet Stimulant Laxative, Laxit, Modane


Adult Dosing

  • 5-30mg PO daily
  • 10mg suppository daily


Pediatric Dosing

  • 6-11 yrs: 5mg or rectally daily

Special Populations

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:


Contraindications

  • Allergy to class/drug
  • Appendicitis
  • Bowel obstruction
  • Gastroenteritis

Adverse Reactions

Serious

  • Colonic atony

Common

  • Abdominal discomfort/colic, diarrhea, proctitis (with suppository use)

Pharmacology

  • Half-life: 8 hr
  • Metabolism: Metabolized to BHPM in the colon
  • Excretion: Urine and bile


Mechanism of Action

  • Stimulates peristalsis via parasympathetic reflexes

Comments

See Also

References

  • Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  • Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  • Christie J, Rose S. Constipation, diarrhea, hemorrhoids, and fecal incontinence. In: Pregnancy in gastrointestinal disorders. Bethesda (MD): ACG Monograph American College of Physicians; 2007. p. 4–9. Available at https://www.acg.gi.org
  • Ducodyl (bisacodyl) [prescribing information]. Troy, MI: Prime Marketing; received January 2019.
  • Friedrich C, Richter E, Trommeshauser D, et al, "Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate Into Human Breast Milk: An Open-Label, Parallel-Group, Multiple-Dose Study in Healthy Lactating Women," Drug Metab Pharmacokinet, 2011, 26(5):458-64. [PubMed 21697613]
  • "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics.1997;99(2):268-278. [PubMed 9024461]
  • Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. [PubMed 24345831]